GSK Plans A $2.5 Billion Restructure to Expedite the Development of New Medications
GSK Plans A $2.5 Billion Restructure to Expedite the Development of New Medications As CEO Luke Miels strives to fulfill his pledge of accelerated drug development, GSK (GSK.L) opened a…